**RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven DR5 hyperclustering and tumor cell apoptosis**

Brünker et al Supplementary Results 2

- Supplementary Table 3

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Apoptosis induction mAb082\_drozitumab** | | **Apoptosis induction DP47GS\_drozitumab** |
| **Tumor cell line** | **DR5 expression** | **Maximum fold-induction (A.U.)** | **EC50 (nM)** | **EC50 (nM)** |
| A549 | Low | 4.5 | 0.2 | N.D. |
| MDA-MB-231 | Moderate | 10.9 | 0.09 | N.D. |
| Colo205 | Moderate | 5.5 | 0.11 | 1.49 |
| DLD-1 | High | 12 | 0.13 | N.D. |
| ACHN | High | 8.76 | 0.49 | N.D. |

**Table S3. FAP-drozitumab antibody-mediated apoptosis does not correlate with DR5 expression levels.** Analysis of tumor cell apoptosis in co-culture with FAP-expressing GM05389 fibroblasts in response to mAb082\_drozitumab or DP47GS\_drozitumab non-targeting control. Maximum apoptosis, calculated as fold-induction over untreated cells, and EC50 values obtained from graphs in Figure 2 are shown (N.D. = value not determined).